Decibel Cannabis Valuation
Is DB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of DB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: DB (CA$0.07) is trading below our estimate of fair value (CA$1.13)
Significantly Below Fair Value: DB is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DB?
Key metric: As DB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is DB's PS Ratio? | |
|---|---|
| PS Ratio | 0.3x |
| Sales | CA$105.60m |
| Market Cap | CA$28.77m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.7x |
| Enterprise Value/EBITDA | 7.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does DB's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.4x | ||
LABS MediPharm Labs | 0.7x | 18.1% | CA$28.8m |
TIUM.U Cansortium | 0.2x | n/a | US$24.2m |
ROMJ Rubicon Organics | 0.5x | 9.4% | CA$21.5m |
RWB Red White & Bloom Brands | 0.3x | n/a | CA$23.5m |
DB Decibel Cannabis | 0.3x | 11.8% | CA$28.8m |
Price-To-Sales vs Peers: DB is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (0.4x).
Price to Sales Ratio vs Industry
How does DB's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?
| 31 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 0.8x | 10.6% | |
DB Decibel Cannabis | 0.3x | 11.8% | US$20.42m |
AYR.A Ayr Wellness | 0.2x | 2.6% | US$89.06m |
IAN iAnthus Capital Holdings | 0.3x | n/a | US$47.37m |
| 31 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 0.8x | 54.4% | |
DB Decibel Cannabis | 0.3x | 150.5% | US$20.42m |
Price-To-Sales vs Industry: DB is good value based on its Price-To-Sales Ratio (0.3x) compared to the Canadian Pharmaceuticals industry average (0.8x).
Price to Sales Ratio vs Fair Ratio
What is DB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.3x |
| Fair PS Ratio | 0.6x |
Price-To-Sales vs Fair Ratio: DB is good value based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CA$0.065 | CA$0.27 +310.3% | 23.4% | CA$0.35 | CA$0.20 | n/a | 3 |
| Nov ’25 | CA$0.07 | CA$0.27 +281.0% | 23.4% | CA$0.35 | CA$0.20 | n/a | 3 |
| Oct ’25 | CA$0.055 | CA$0.32 +475.8% | 26.8% | CA$0.40 | CA$0.20 | n/a | 3 |
| Sep ’25 | CA$0.065 | CA$0.32 +387.2% | 26.8% | CA$0.40 | CA$0.20 | n/a | 3 |
| Aug ’25 | CA$0.055 | CA$0.37 +566.7% | 28.0% | CA$0.50 | CA$0.25 | n/a | 3 |
| Jul ’25 | CA$0.05 | CA$0.42 +750.0% | 17.6% | CA$0.50 | CA$0.35 | n/a | 2 |
| Jun ’25 | CA$0.07 | CA$0.37 +423.8% | 28.0% | CA$0.50 | CA$0.25 | n/a | 3 |
| May ’25 | CA$0.13 | CA$0.38 +206.7% | 22.2% | CA$0.50 | CA$0.30 | n/a | 3 |
| Apr ’25 | CA$0.13 | CA$0.45 +260.0% | 24.0% | CA$0.60 | CA$0.35 | n/a | 3 |
| Mar ’25 | CA$0.12 | CA$0.45 +275.0% | 24.0% | CA$0.60 | CA$0.35 | n/a | 3 |
| Feb ’25 | CA$0.14 | CA$0.45 +233.3% | 24.0% | CA$0.60 | CA$0.35 | n/a | 3 |
| Jan ’25 | CA$0.13 | CA$0.45 +246.2% | 24.0% | CA$0.60 | CA$0.35 | n/a | 3 |
| Dec ’24 | CA$0.14 | CA$0.50 +257.1% | 20.0% | CA$0.60 | CA$0.40 | n/a | 2 |
| Nov ’24 | CA$0.14 | CA$0.50 +270.4% | 20.0% | CA$0.60 | CA$0.40 | CA$0.07 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Fennec Pharmaceuticals
US$109.5m
Operates as a biopharmaceutical company in the United States.
FRX
US$5.68
7D
-3.6%
1Y
-49.7%
Medexus Pharmaceuticals
CA$52.3m
Operates as a pharmaceutical company in Canada and the United States.
MDP
CA$2.24
7D
10.3%
1Y
42.7%
Verano Holdings
CA$845.9m
Operates as a vertically integrated multi-state cannabis operator in the United States.
VRNO
CA$2.39
7D
14.9%
1Y
-59.1%